medalphabetМедицинский алфавитMedical alphabet2078-56312949-2807ООО «Альфмед»10.33667/2078-5631-2024-20-9-12medalphabet-3911Research ArticleСтатьиЖидкостная биопсия: анализ циркулирующей опухолевой ДНК кровиLiquid biopsy: the analysis of circulating tumour DNAhttps://orcid.org/0000-0002-0266-7015ЩербоД. С.ShcherboD. S.

Щербо Дмитрий Сергеевич к.б.н., доцент, с.н.с. WoS Researcher ID B-3549–2019. Scopus Author iD 18435270800.

Москва

Shcherbo Dmitry S. - PhD Bio, associate professor, senior researcher. WoS Researcher ID B-3549–2019. Scopus Author iD 18435270800.

Moscow

shcherbos@mail.ruКовальА. П.KovalA. P.

Коваль Анастасия Павловна научный сотрудник лаборатории биомаркеров НИИ Трансляционной медицины. WoS Researcher ID ААB-5984–2020. Scopus Author iD 8618442700.

Москва

Koval Anastasia P. - researcher at the Laboratory of Biomarkers, Research Institute of Translational Medicine. WoS Researcher ID AAB-5984–2020. Scopus Author iD 8618442700.

Moscow

https://orcid.org/0000-0002-0266-7015ЩербоС. Н.ShcherboS. N.

Щербо Дмитрий Сергеевич к.б.н., доцент, с.н.с. WoS Researcher ID B-3549–2019. Scopus Author iD 18435270800.

Москва

Shcherbo Sergei N. - Dr Bio Sci (habil.), professor, head of Clinical Laboratory Diagnostics Dept, Faculty of postgraduate education. WoS Researcher ID К-9314–2018. Scopus Author iD 6602618674.

Moscow

shcherbos@mail.ruСавинаМ. И.SavinaM. I.

Савина Марина Ивановна - д.б.н., проф. кафедры клинической лабораторной диагностики ФДПО.

Москва

Savina Marina I. - Dr Bio Sci (habil.), professor at Clinical Laboratory Diagnostics Dept, Faculty of postgraduate education.

Moscow

ТуркинаТ. И.TurkinaT. I.

Туркина Татьяна Ивановна д.б.н., проф. кафедры клинической лабораторной диагностики ФДПО.

Москва

Turkina Tatiana I. - Dr Bio Sci (habil.), professor at Clinical Laboratory Diagnostics Dept, Faculty of postgraduate education.

Moscow

ФГАОУ ВО «Российский национальный исследовательский медицинский университет имени Н. И. Пирогова» Минздрава РоссииРоссияN.I. Pirogov Russian National Research Medical UniversityRussian Federation202401112024020Серия «Современная лаборатория» (2)912Copyright © Щербо Д.С., Коваль А.П., Щербо С.Н., Савина М.И., Туркина Т.И., 20242024Щербо Д.С., Коваль А.П., Щербо С.Н., Савина М.И., Туркина Т.И.Shcherbo D.S., Koval A.P., Shcherbo S.N., Savina M.I., Turkina T.I.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-alphabet.com/jour/article/view/3911

Циркулирующие в крови фрагменты ДНК опухолевого происхождения (цоДНК) служат важным источником информации об опухоли. Анализ цоДНК осложняется присутствием избытка ДНК из нормальных клеток и требует разработки высокочувствительных лабораторных методов. В обзоре рассматриваются основные типы биомаркеров цоДНК и особенности их детекции, а также направления развития перспективных технологий в области жидкостной биопсии.

Circulating tumour DNA (ctDNA) fragments found in blood represent a critical source of information about the tumour. However, the analysis of ctDNA is challenging due to the overwhelming presence of DNA from non-malignant cells and requires the development of highly sensitive laboratory techniques. This review discusses the major categories of ctDNA biomarkers, their detection methodologies, and explores the potential of emerging technologies within the liquid biopsy field.

жидкостная биопсиякровьонкодиагностикациркулирующие фрагменты ДНК опухолевого происхождения (цоДНК)обзорliquid biopsybloodoncodiagnosticscirculating fragments of tumor DNA (ctDNA)reviewReferencesVogelstein B., Papadopoulos N., Velculescu V. E. et al. 2013. “Cancer Genome Landscapes.” Science 339 (6127): 1546–58.Vogelstein B., Papadopoulos N., Velculescu V. E. et al. 2013. “Cancer Genome Landscapes.” Science 339 (6127): 1546–58.Mamatjan Y, Agnihotri S., Goldenberg A. et al. 2017. “Molecular Signatures for Tumor Classification: An Analysis of The Cancer Genome Atlas Data.” The Journal of Molecular Diagnostics: JMD 19 (6): 881–91.Mamatjan Y, Agnihotri S., Goldenberg A. et al. 2017. “Molecular Signatures for Tumor Classification: An Analysis of The Cancer Genome Atlas Data.” The Journal of Molecular Diagnostics: JMD 19 (6): 881–91.Doherty G. J., Petruzzelli M., Beddowes E. 2019. “Cancer Treatment in the Genomic Era.” Annual Review of Biochemistry 88 (June):247–80.Doherty G. J., Petruzzelli M., Beddowes E. 2019. “Cancer Treatment in the Genomic Era.” Annual Review of Biochemistry 88 (June):247–80.Heitzer E., Haque I. S., Roberts Ch. Et al. 2019. “Current and Future Perspectives of Liquid Biopsies in Genomics-Driven Oncology.” Nature Reviews. Genetics 20 (2): 71–88.Heitzer E., Haque I. S., Roberts Ch. Et al. 2019. “Current and Future Perspectives of Liquid Biopsies in Genomics-Driven Oncology.” Nature Reviews. Genetics 20 (2): 71–88.Mandel P., Metais P. 1948. “Les Acides Nucléiques Du Plasma Sanguin Chez L’homme.” Comptes Rendus Des Seances de La Societe de Biologie et de Ses Filiales 142 (3–4): 241–43.Mandel P., Metais P. 1948. “Les Acides Nucléiques Du Plasma Sanguin Chez L’homme.” Comptes Rendus Des Seances de La Societe de Biologie et de Ses Filiales 142 (3–4): 241–43.Alix-Panabières C., Pantel K. 2016. “Clinical Applications of Circulating Tumor Cells and Circulating Tumor DNA as Liquid Biopsy.” Cancer Discovery 6 (5): 479–91.Alix-Panabières C., Pantel K. 2016. “Clinical Applications of Circulating Tumor Cells and Circulating Tumor DNA as Liquid Biopsy.” Cancer Discovery 6 (5): 479–91.Kalluri R., LeBleu V.S. 2016. “Discovery of Double-Stranded Genomic DNA in Circulating Exosomes.” Cold Spring Harbor Symposia on Quantitative BiologyKalluri R., LeBleu V.S. 2016. “Discovery of Double-Stranded Genomic DNA in Circulating Exosomes.” Cold Spring Harbor Symposia on Quantitative BiologyDelgado P. O., Alves B., Gehrke F. et al. 2013. “Characterization of Cell-Free Circulating DNA in Plasma in Patients with Prostate Cancer.” Tumour Biology: The Journal of the International Society for Oncodevelopmental Biology and Medicine 34 (2): 983–86.Delgado P. O., Alves B., Gehrke F. et al. 2013. “Characterization of Cell-Free Circulating DNA in Plasma in Patients with Prostate Cancer.” Tumour Biology: The Journal of the International Society for Oncodevelopmental Biology and Medicine 34 (2): 983–86.Mattox A. K., Douville Ch, Wang Y. et al. 2023. “The Origin of Highly Elevated Cell-Free DNA in Healthy Individuals and Patients with Pancreatic, Colorectal, Lung, or Ovarian Cancer.” Cancer Discovery, August. https://doi.org/10.1158/2159–8290.CD-21–1252.Mattox A. K., Douville Ch, Wang Y. et al. 2023. “The Origin of Highly Elevated Cell-Free DNA in Healthy Individuals and Patients with Pancreatic, Colorectal, Lung, or Ovarian Cancer.” Cancer Discovery, August. https://doi.org/10.1158/2159–8290.CD-21–1252.Stroun M., Lyautey J., Lederrey C., et al. 2001. “About the Possible Origin and Mechanism of Circulating DNA Apoptosis and Active DNA Release.” Clinica Chimica Acta; International Journal of Clinical Chemistry 313 (1–2): 139–42.Stroun M., Lyautey J., Lederrey C., et al. 2001. “About the Possible Origin and Mechanism of Circulating DNA Apoptosis and Active DNA Release.” Clinica Chimica Acta; International Journal of Clinical Chemistry 313 (1–2): 139–42.Kidess E., Jeffrey S. 2013. “Circulating Tumor Cells versus Tumor-Derived Cell-Free DNA: Rivals or Partners in Cancer Care in the Era of Single-Cell Analysis?” Genome Medicine 5 (8): 70.Kidess E., Jeffrey S. 2013. “Circulating Tumor Cells versus Tumor-Derived Cell-Free DNA: Rivals or Partners in Cancer Care in the Era of Single-Cell Analysis?” Genome Medicine 5 (8): 70.Ignatiadis M., Lee M., Jeffrey S. 2015. “Circulating Tumor Cells and Circulating Tumor DNA: Challenges and Opportunities on the Path to Clinical Utility.” Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 21 (21): 4786–4800.Ignatiadis M., Lee M., Jeffrey S. 2015. “Circulating Tumor Cells and Circulating Tumor DNA: Challenges and Opportunities on the Path to Clinical Utility.” Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 21 (21): 4786–4800.13. Bettegowda Ch., Sausen M., Leary R. et al. 2014. “Detection of Circulating Tumor DNA in Earlyand Late-Stage Human Malignancies.” Science Translational Medicine 6 (224): 224ra24.13. Bettegowda Ch., Sausen M., Leary R. et al. 2014. “Detection of Circulating Tumor DNA in Earlyand Late-Stage Human Malignancies.” Science Translational Medicine 6 (224): 224ra24.Swarup V., Rajeswari M. 2007. “Circulating (cell-Free) Nucleic Acids – a Promising, Non-Invasive Tool for Early Detection of Several Human Diseases.” FEBS Letters 581 (5): 795–99.Swarup V., Rajeswari M. 2007. “Circulating (cell-Free) Nucleic Acids – a Promising, Non-Invasive Tool for Early Detection of Several Human Diseases.” FEBS Letters 581 (5): 795–99.Newman A. M., Bratman S. V., To J. et al. 2014. “An Ultrasensitive Method for Quantitating Circulating Tumor DNA with Broad Patient Coverage.” Nature Medicine 20 (5): 548–54.Newman A. M., Bratman S. V., To J. et al. 2014. “An Ultrasensitive Method for Quantitating Circulating Tumor DNA with Broad Patient Coverage.” Nature Medicine 20 (5): 548–54.Abbosh Ch., Birkbak N. J., Wilson G. A. et al. 2017. “Phylogenetic ctDNA Analysis Depicts Early-Stage Lung Cancer Evolution.” Nature 545 (7655): 446–51.Abbosh Ch., Birkbak N. J., Wilson G. A. et al. 2017. “Phylogenetic ctDNA Analysis Depicts Early-Stage Lung Cancer Evolution.” Nature 545 (7655): 446–51.Watanabe K., Nakamura Y., Low S-K. 2021. “Clinical Implementation and Current Advancement of Blood Liquid Biopsy in Cancer.” Journal of Human Genetics 66 (9): 909–26.Watanabe K., Nakamura Y., Low S-K. 2021. “Clinical Implementation and Current Advancement of Blood Liquid Biopsy in Cancer.” Journal of Human Genetics 66 (9): 909–26.Reckamp K. L., Melnikova V. O., Karlovich Ch. et al. 2016. “A Highly Sensitive and Quantitative Test Platform for Detection of NSCLC EGFR Mutations in Urine and Plasma.” Journal of Thoracic Oncology: Official Publication of the International Association for the Study of Lung Cancer 11 (10): 1690–1700.Reckamp K. L., Melnikova V. O., Karlovich Ch. et al. 2016. “A Highly Sensitive and Quantitative Test Platform for Detection of NSCLC EGFR Mutations in Urine and Plasma.” Journal of Thoracic Oncology: Official Publication of the International Association for the Study of Lung Cancer 11 (10): 1690–1700.Deveson I. W., Gong B., Lai K. et al. 2021. “Evaluating the Analytical Validity of Circulating Tumor DNA Sequencing Assays for Precision Oncology.” Nature Biotechnology, April, 1–14.Deveson I. W., Gong B., Lai K. et al. 2021. “Evaluating the Analytical Validity of Circulating Tumor DNA Sequencing Assays for Precision Oncology.” Nature Biotechnology, April, 1–14.Nielsen H. J., Anagnostou V., Fijneman R. et al. 2017. “Direct Detection of Early-Stage Cancers Using Circulating Tumor DNA.” Science Translational Medicine 9 (403): eaan2415.Nielsen H. J., Anagnostou V., Fijneman R. et al. 2017. “Direct Detection of Early-Stage Cancers Using Circulating Tumor DNA.” Science Translational Medicine 9 (403): eaan2415.Wan Jonathan C. M., Heider K., Gale D. et al. 2020. “ctDNA Monitoring Using Patient-Specific Sequencing and Integration of Variant Reads.” Science Translational Medicine 12 (548): eaaz8084.Wan Jonathan C. M., Heider K., Gale D. et al. 2020. “ctDNA Monitoring Using Patient-Specific Sequencing and Integration of Variant Reads.” Science Translational Medicine 12 (548): eaaz8084.Cohen J. D., Li L., Wang Y. et al. 2018. “Detection and Localization of Surgically Resectable Cancers with a Multi-Analyte Blood Test.” Science 3247 (January): eaar3247.Cohen J. D., Li L., Wang Y. et al. 2018. “Detection and Localization of Surgically Resectable Cancers with a Multi-Analyte Blood Test.” Science 3247 (January): eaar3247.Warren J. D., Xiong W., Bunker A. M.et al. 2011. “Septin 9 Methylated DNA Is a Sensitive and Specific Blood Test for Colorectal Cancer.” BMC Medicine 9 (December):133.Warren J. D., Xiong W., Bunker A. M.et al. 2011. “Septin 9 Methylated DNA Is a Sensitive and Specific Blood Test for Colorectal Cancer.” BMC Medicine 9 (December):133.Shen Sh. Y., Singhania R., Fehringer G. et al. 2018. “Sensitive Tumour Detection and Classification Using Plasma Cell-Free DNA Methylomes.” Nature. https://doi.org/10.1038/s41586–018–0703–0.Shen Sh. Y., Singhania R., Fehringer G. et al. 2018. “Sensitive Tumour Detection and Classification Using Plasma Cell-Free DNA Methylomes.” Nature. https://doi.org/10.1038/s41586–018–0703–0.Liu M. C., Oxnard G. R., Klein E. A. et al. 2020. “Sensitive and Specific Multi-Cancer Detection and Localization Using Methylation Signatures in Cell-Free DNA.” Annals of Oncology: Official Journal of the European Society for Medical Oncology / ESMO xxx (xxx). https://doi.org/10.1016/j.annonc.2020.02.011.Liu M. C., Oxnard G. R., Klein E. A. et al. 2020. “Sensitive and Specific Multi-Cancer Detection and Localization Using Methylation Signatures in Cell-Free DNA.” Annals of Oncology: Official Journal of the European Society for Medical Oncology / ESMO xxx (xxx). https://doi.org/10.1016/j.annonc.2020.02.011.Chung D. C., Gray II D.M., Singh H. et al. 2024. “A Cell-Free DNA Blood-Based Test for Colorectal Cancer Screening.” The New England Journal of Medicine 390 (11): 973–83.Chung D. C., Gray II D.M., Singh H. et al. 2024. “A Cell-Free DNA Blood-Based Test for Colorectal Cancer Screening.” The New England Journal of Medicine 390 (11): 973–83.Schwarzenbach H., Nishida N., Calin G., Pantel K. 2014. “Clinical Relevance of Circulating Cell-Free microRNAs in Cancer.” Nature Reviews. Clinical Oncology 11 (3): 145–56.Schwarzenbach H., Nishida N., Calin G., Pantel K. 2014. “Clinical Relevance of Circulating Cell-Free microRNAs in Cancer.” Nature Reviews. Clinical Oncology 11 (3): 145–56.Mayers J. R., Wu Ch, Clish C. et al. 2014. “Elevation of Circulating Branched-Chain Amino Acids Is an Early Event in Human Pancreatic Adenocarcinoma Development.” Nature Medicine 20 (10): 1193–98.Mayers J. R., Wu Ch, Clish C. et al. 2014. “Elevation of Circulating Branched-Chain Amino Acids Is an Early Event in Human Pancreatic Adenocarcinoma Development.” Nature Medicine 20 (10): 1193–98.Lapin M., Oltedal S., Tjensvoll K. et al. 2018. “Fragment Size and Level of Cell-Free DNA Provide Prognostic Information in Patients with Advanced Pancreatic Cancer.” Journal of Translational Medicine 16 (1): 300.Lapin M., Oltedal S., Tjensvoll K. et al. 2018. “Fragment Size and Level of Cell-Free DNA Provide Prognostic Information in Patients with Advanced Pancreatic Cancer.” Journal of Translational Medicine 16 (1): 300.Cristiano S., Leal A., Phallen J. et al. 2019. “Genome-Wide Cell-Free DNA Fragmentation in Patients with Cancer.” Nature 570 (7761): 385–89.Cristiano S., Leal A., Phallen J. et al. 2019. “Genome-Wide Cell-Free DNA Fragmentation in Patients with Cancer.” Nature 570 (7761): 385–89.Sun K., Jiang P., Cheng S. et al. 2019. “Orientation-Aware Plasma Cell-Free DNA Fragmentation Analysis in Open Chromatin Regions Informs Tissue of Origin.” Genome Research 29 (3): 418–27.Sun K., Jiang P., Cheng S. et al. 2019. “Orientation-Aware Plasma Cell-Free DNA Fragmentation Analysis in Open Chromatin Regions Informs Tissue of Origin.” Genome Research 29 (3): 418–27.Corcoran R. B. 2019. “Circulating Tumor DNA: Clinical Monitoring and Early Detection.” Annual Review of Cancer Biology 3 (1): 187–201.Corcoran R. B. 2019. “Circulating Tumor DNA: Clinical Monitoring and Early Detection.” Annual Review of Cancer Biology 3 (1): 187–201.

The authors declare that there are no conflicts of interest present.